[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355004-105":59,"doc-detail-355004-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","neuroendocrine-neoplasms-of-the-gastrointestinal-tract-morphology-who-2022-grading-and-prognostic-perspectives","Neuroendocrine Neoplasms of the Gastrointestinal Tract - Morphology, WHO 2022 Grading, and Prognostic Perspectives","","Gastrointestinal neuroendocrine neoplasms (GI NENs) form a heterogeneous tumor group with variable morphology, proliferative behavior, and clinical outcomes. Their incidence continues rising worldwide due to improved detection and expanding neuroendocrine biology knowledge. This narrative review integrates morphologic, immunohistochemical, and molecular features across anatomic sites, focusing on WHO 2022 grade prognostic impact, diagnostic challenges (NET G3 vs NEC, MiNENs), and variability sources such as Ki-67 interpretation and sampling limits, while outlining emerging biomarkers and therapeutic directions including PRRT and systemic chemotherapy alongside precision oncology.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neuroendocrine-neoplasms-of-the-gastrointestinal-tract-morphology-who-2022-grading-and-prognostic-perspectives/355004/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neuroendocrine-neoplasms-of-the-gastrointestinal-tract-morphology-who-2022-grading-and-prognostic-perspectives/355004.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the review cover about gastrointestinal neuroendocrine neoplasms (GI NENs)?","Question",{"text":113,"@type":114},"It synthesizes morphologic, immunohistochemical, and molecular features of GI NENs across anatomic sites, emphasizing diagnostic advances and the prognostic significance of the WHO 2022 grade.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What key diagnostic challenges are highlighted?",{"text":118,"@type":114},"The review examines differentiating NET grade 3 from neuroendocrine carcinoma and accurately assessing mixed neuroendocrine-non-neuroendocrine neoplasms, including variability from Ki-67 interpretation and sampling limitations.",{"name":120,"@type":111,"acceptedAnswer":121},"Which emerging prognostic and clinical directions are discussed?",{"text":122,"@type":114},"It reviews emerging prognostic biomarkers, digital pathology applications, and evolving therapeutic strategies such as somatostatin analogs, peptide receptor radionuclide therapy (PRRT), and systemic chemotherapy in precision oncology.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355004,1790231845,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Received 12/08/2025  \nReview began 12/14/2025  \nReview ended 12/27/2025  \nPublished 01/06/2026  \n© Copyright 2026  \nQasim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.100913  \nOpen Access Review Article  \n Published via Fondazione Paolo Procacci  \nNeuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives  \nHussein Qasim 1, Shaima ' Dibian 1, Mohammad Abu Shugaer 1, Karis Khattab 2, Mudhaffer Touqan 3, Matteo Luigi Giuseppe Leoni 4 , Giustino Varrassi 5  \n1. Pathology and Laboratory Medicine, Jordan University of Science and Technology, Irbid, JOR 2. Medicine, Jordan University of Science and Technology, Irbid, JOR 3. Emergency Medicine, Azraq Refugee Camp Hospital International Medical Corps, Amman, JOR 4. Medical and Surgical Sciences and Translational Medicine, Sapienza University, Rome, ITA 5. Pain Medicine, Fondazione Paolo Procacci, Rome, ITA  \nCorresponding author: Karis Khattab, [kariskhattab@gmail.com](kariskhattab@gmail.com)  \nAbstract  \nGastrointestinal neuroendocrine neoplasms (GI NENs) represent a heterogeneous group of tumors distinguished by variable morphology, proliferative behavior, and clinical outcomes. Their incidence continues to rise globally, driven by improved detection methods and increased understanding of neuroendocrine biology. This narrative review synthesizes current knowledge on the morphologic, immunohistochemical, and molecular features of GI NENs across anatomic sites, highlighting advances in diagnostic evaluation and the prognostic significance of the WHO 2022 grade. Key diagnostic challenges, including differentiating neuroendocrine tumor grade 3 (NET G3) from neuroendocrine carcinoma (NEC) and accurately assessing mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs), are examined alongside sources of variability such as Ki-67 interpretation and sampling limitations. Emerging prognostic biomarkers, digital pathology applications, and evolving therapeutic strategies, particularly somatostatin analogs, peptide receptor radionuclide therapy, and systemic chemotherapy, are reviewed in the context of precision oncology. Continued integration of molecular profiling, artificial intelligence, and standardized diagnostic approaches promises to refine prognostication and personalize management for patients with GINENs.  \nCategories: Pathology, Internal Medicine, Gastroenterology  \nKeywords: gastrointestinal neuroendocrine neoplasms, ki-67, minen, net g3, neuroendocrine carcinomas,  \nneuroendocrine tumors, who 2022 classification  \nIntroduction And Background  \nNeuroendocrine neoplasms (NENs) of the gastrointestinal (GI) tract represent a biologically diverse and increasingly recognized group of tumors arising from neuroendocrine cells dispersed throughout the mucosa and submucosa of the digestive system [1] . These cells, which play a critical role in regulating gut motility, secretion, and metabolic homeostasis, can give rise to neoplasms ranging from indolent, well-differentiated tumors to highly aggressive carcinomas with rapid progression and poor clinical outcomes [2] . Over the past two decades, the incidence of GI NENs has risen steadily worldwide, a trend attributed not only to evolving molecular insights and heightened clinical awareness but also to improvements in endoscopic detection, radiologic imaging, and histopathologic surveillance [3] . As a result, NENs now constitute one of the fastestgrowing categories of GI malignancies in epidemiologic registries [4] .  \nHistorically referred to as “carcinoid tumors,” GI NENs were once viewed as largely benign or low-grade lesions. However, contemporary research has demonstrated that these neoplasms exhibit a wide spectrum of biological behavior driven b","cbCaijx57h29YPJH","https://ap.wps.com/l/cbCaijx57h29YPJH","pdf",1162927,15,"English","# Introduction And Background\n## WHO 2022 classification and proliferation-based grading\n## Diagnostic implications of Grade 3 NETs vs NECs\n# Abstract Themes\n## Morphologic, immunohistochemical, and molecular features\n## Diagnostic challenges and sources of variability\n## Prognostic biomarkers and emerging applications\n# How to cite","[{\"question\":\"What does the review cover about gastrointestinal neuroendocrine neoplasms (GI NENs)?\",\"answer\":\"It synthesizes morphologic, immunohistochemical, and molecular features of GI NENs across anatomic sites, emphasizing diagnostic advances and the prognostic significance of the WHO 2022 grade.\"},{\"question\":\"What key diagnostic challenges are highlighted?\",\"answer\":\"The review examines differentiating NET grade 3 from neuroendocrine carcinoma and accurately assessing mixed neuroendocrine-non-neuroendocrine neoplasms, including variability from Ki-67 interpretation and sampling limitations.\"},{\"question\":\"Which emerging prognostic and clinical directions are discussed?\",\"answer\":\"It reviews emerging prognostic biomarkers, digital pathology applications, and evolving therapeutic strategies such as somatostatin analogs, peptide receptor radionuclide therapy (PRRT), and systemic chemotherapy in precision oncology.\"}]","Neuroendocrine Neoplasms of the Gastrointestinal Tract - Morphology, WHO 2022 Grading, and Prognostic Perspectives | PDF",1790115337,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/782aa6cdc2bcc41f5c78f3a702452c28.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/112ed11e5d572dd814a9acd6afa41ed4.webp",982,1389,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/935fbdee3275627f665b38fe953fe635.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01fc3b9e0c943da2a232c959a0e5d7cf.webp",980,1386]